The immuno-oncology therapy developer has amassed at least $190m of overall funding since emerging out of Stanford University.

Synthekine, a US-based immuno-oncology therapy spinout of Stanford University, has raised $108m in a series B round co-led by Deerfield Management and Janus Henderson Investors. Lilly Asia Ventures, a corporate venturing vehicle for pharmaceutical firm Eli Lilly. RA Capital Management, Rock Springs Capital, Omega Funds, Samsara BioCapital, Canaan Partners, Emerson Collective, Column Group and its affiliate TCG Crossover, as well as an undisclosed healthcare investor also took part. Founded in 2018, Synthekine is studying engineered cytokine – molecules secreted by specific cells in the immune system – to develop treatments for patients with cancer and autoimmune disorders. The capital injection will support clinical studies for Synthekine’s therapeutic pipeline. Its lead candidate, STK-012, is a partial agonist that can induce anti-tumour activity without the toxicities commonly associated with therapeutics based on the cytokine interleukin-2. The company’s technology platform was developed by Christopher Garcia, a professor of molecular and cellular physiology and structural biology at Stanford University School of Medicine. Synthekine has raised at least $190m of funding to date. In September 2020, Synthekine raised $82m of series A funding in a round co-led by Canaan Partners, Samsara BioCapital and Column Group investing together with unnamed participants. Emerson Collective was described as an existing investor in the series B announcement. – A version of this article first appeared on our sister site, Global Corporate Venturing.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?